The global Plasma Protease C1 Inhibitor market is anticipated to increase at a 18.2% CAGR to reach value US$ 10,603.4 Million in 2028
.jpg "The Global Plasma Protease C1 Inhibitor Market 2018-2028 (USD Million)")
Factors driving the growth of the plasma protease C1 inhibitor market include growing emphasis of biopharmaceutical companies on the development of effective therapies for treating various health disorders, increasing product consents and increasing research & development.
Hereditary angioneurotic edema (HANE) is due to the functional deficiency of the mold inhibitor of the first component of human complement (C1-Inh). This protease inhibitor is involved in the regulation of several proteolytic systems in plasma protein therapeutic including the complement system, the contact system of intrinsic coagulation and kinin release, and the fibrinolytic system.
Regionally, North America accounted for the largest market share of the global plasma protease C1 inhibitor market attributable to the existence of well-established healthcare infrastructure. Leading players of the global plasma protease C1 inhibitor market include include KalVista Pharmaceuticals, Inc., CSL Behring LLC, Lonis Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Pharming Technologies B.V., BioCryst Pharmaceuticals, Centogene AG, among others.
Plasma Protease C1 Inhibitor Market
| Metrics | Details |
| Base Year | 2023 |
| Historic Data | 2018-2022 |
| Forecast Period | 2024-2028 |
| Study Period | 2018-2028 |
| Forecast Unit | Value (USD) |
| Revenue forecast in 2028 | US$ 10,603.4 Million |
| Growth Rate | CAGR of 18.2 % during 2018-2028 |
| Segment Covered | By Drug Type, By Dosage, Regions |
| Regions Covered | North America, Europe, Asia Pacific, Middle East and Africa, South America |
| Key Players Profiled | KalVista Pharmaceuticals, Inc., CSL Behring LLC, Lonis Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Pharming Technologies B.V., BioCryst Pharmaceuticals, Centogene AG, among others. |
Key segments of the global plasma protease C1 inhibitor market
Drug Type Overview
- C1-inhibitors
- Kallikrein inhibitor
- Selective bradykinin b2 receptor antagonist
Dosage Form
- Lyophilized
- Injectable
Regional Overview
- North America
- U.S.
- Canada
- Europe
- Germany
- United Kingdom
- France
- Asia Pacific
- China
- Japan
- India
- South America
- Brazil
- Mexico
- Middle East & Africa
- GCC
- South Africa
Frequently Asked Questions (FAQ) :
The major contenders in the global market are KalVista Pharmaceuticals, Inc., CSL Behring LLC, Lonis Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Pharming Technologies B.V., BioCryst Pharmaceuticals, Centogene AG, among others.
North America dominated the market for plasma protease c1 inhibitor market and accounted for the largest revenue share.
The plasma protease c1 inhibitor market is growing at a CAGR of 18.2 % over the forecast period.
Angioedema in the absence of allergy continues to represent a medical paradox. This uncommon disorder may manifest as facial, laryngeal, genital, or intraabdominal swelling or swelling of the extremities. Despite its often dramatic presentation, its rarity and its tendency to mimic other, dissimilar disease states often obscure its diagnosis. Even so, the condition has been documented for more than a century. However, work has been undertaken to better understand the genetics, pathogenesis, and appropriate clinical management of angioedema. However, today hereditary angioedema (HAE) and its even rarer acquired form, acquired angioedema (AAE), remain little known in clinical practice and thus frequently misdiagnosed and inappropriately treated, often resulting in unnecessary suffering.
The global plasma protease C1 inhibitor market is categorized based on drug type and dosage form. By drug type, the C1-inhibitors was the largest market in 2020 while the bradykinin B2 receptor antagonist is set to grow at a highest CAGR by 2028. C1-inhibitors are recognized to directly hinder with the attraction of mingling leukocytes through inflammatory reactions and use of C1-inhibitor has been demonstrated to be advantageous in ischemia-reperfusion impairment in a number of organs.
HAE and AAE present an ongoing clinical challenge. Despite the recurrent nature of angioedema attacks, their acute treatment is often suboptimal, sometimes delayed, and often requires lengthy hospital stays. In some countries, including the United States, no safe and effective acute attack therapy is available. Even the prophylactic management of these disorders is inconsistent across centers and nations, and, because of the side effects of antifibrinolytics and steroids currently in use, requires a lifelong, individualized calculation of benefits and risks. These drawbacks are well known to the small community of physicians who deal frequently with these diseases and are a feature of life for those patients who suffer frequent or severe attacks.